PF375 IBRUTINIB AND RITUXIMAB AS FRONT-LINE TREATMENT FOR UNFIT PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA (CLL). PRELIMINARY RESULTS FROM THE GIMEMA LLC1114 STUDY

Autor:	Caterina Stelitano, Mauro Nanni, Marta Coscia, Enrico Crea, Massimo Gentile, L Laurenti, Adalberto Ibatici, I. Del Giudice, Attilio Guarini, Alessandro Gozzetti, I. Della Starza, F.R. Mauro, Francesca Re, A. L. Molinari, Fiorella Ilariucci, Donato Mannina, Gianluigi Reda, Sara Raponi, Stefano Molica, Antonino Neri, Monia Marchetti, Daniela Pietrasanta, Robert Foa, P. L. Zinzani, Paola Fazi, Anna Marina Liberati, N. Di Renzo, Giuseppe Specchia, G. Gaidano, Monica Tani, Roberto Marasca, M.S. De Propris, Daniela Gottardi, Livio Trentin, Luca Arcaini, Ugo Consoli, Paolo Sportoletti, Francesca Paoloni, Antonio Cuneo, Roberta Murru, L. Orsucci
Rok vydání:	2019
Předmět:	Oncology medicine.medical_specialty business.industry Chronic lymphocytic leukemia Front line Hematology medicine.disease chemistry.chemical_compound chemistry Internal medicine Ibrutinib Medicine Rituximab business medicine.drug
Zdroj:	HemaSphere. 3:139
ISSN:	2572-9241
DOI:	10.1097/01.hs9.0000559712.15168.1d
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::ad04fd84cba6288200aa9b020f6c5902 https://doi.org/10.1097/01.hs9.0000559712.15168.1d Zobrazit plný text záznamu Plný text